### Formulation for Stability: Moving Beyond Excipient Compatibility

Kenneth C. Waterman, Ph.D. FreeThink Technologies, Inc. Branford, CT USA



### **Reactive Excipients**

- Some degradation due to direct excipientdrug reaction
- Example: Maillard reaction between secondary amines (amino acids) and reducing carbohydrates (e.g., lactose) leads to brown colors + multiple products
- <u>Relatively uncommon</u> (other than this reaction)



## Reaction with Excipient Impurities/Degradants

- Peroxides
- Formaldehyde (and other aldehydes)
- Acids
  - Formic acid
  - Acetic acid



### **Non-reactive Excipient Impact**

- Effects proportional to interfacial contact
- Specific degradation will show different effects
- Some degradation mechanisms will be more sensitive than others to excipients



### Drug Concentration Impact in Solid Formulations


Impact of concentration (<u>approximation</u>):

$$\log k = \alpha \log \frac{100\%}{\% active} + \log k_0$$

- $\alpha$  may be independent of temperature/RH
- α may depend on T/RH (catalysis)



#### Example




From J Pharm Sci 2012, 101, 4170-4177.



ken.waterman@freethinktech.com 2018

### Example




*G. Scrivens; 2017 Presentation from Science of Stability Conference* 



ken.waterman@freethinktech.com 2018

#### Example



### **Excipient Compatibility**

- Binary blend stability (often rank order)
  - 1:1 API:Excipient
  - Representative API level:Excpient level



## Problems with Binary Excipient Compatibility

- For low level excipient, greatly exaggerates issues
  - Often leads to excluding magnesium stearate
- Since true interaction is base on log-log scaling, formulation stability is not a weighted average of the binary stabilities
- Rank order not appropriate
  - Excludes good enough excipients
- Stability studies can be slow delaying product development



# **Screening Stability (Rank Order)**


Two formulations screened 2 weeks, 70°C/75%RH

Formulation	70°C
Α	0.18
В	0.90

# Which formulation should you proceed with for ambient (25°C/60%RH) storage?



Copyright FreeThink Technologies, Inc. 2018 freethinktech.com



# **Screening Stability (Rank Order)**


- Rank order from high temperature often opposite to room temperature
- Rank order does not distinguish formulations that are all good or all bad



### Excipient Compatibility Formulation Development (Real Time Stability)

#### Long development time for stable formulations

#### **Traditional Formulation Development: 6-12 mos.**






### Rapid Formulation Development: ASAPprime<sup>®</sup> Tiered Approach

- Full formulations prepared (e.g., tablets, capsules)
  - 3-4 Tier 1 full formulations
  - Low API concentration (worst case)
- ASAP studies conducted
- Tier 1 formulations work for most APIs and enable fast development
- If Tier 1 fails, Tier 2 formulations used
- Rare that we need to go past this
- Must justify formulation used: do not need excipient compatibility for regulatory submissions.



#### **Rapid Formulation Development**

#### ASAP-Based Formulation Development using Tiers: 1-4 mos.





### **Example Tier 1 Tablet Formulations**

Function	Ingredient	Formulation 1 wt%	Formulation 2 wt%
Active	API	5	5
Diluent (ductile)	MCC	54	54
Diluent (brittle)	Lactose	25	
Diluent (brittle)	Mannitol		25
Disintegrant	Croscarmellose sodium	10	
Disintegrant	Crospovidone		10
Binder	НРС	5	
Binder	Povidone		5
Lubricant	Magnesium stearate	1	
Lubricant	Stearic acid		1



### **Tiered Approach to Formulation Development**

#### Advantages to ASAP Approach

- Fewer resources, much shorter time-line
- Most cases can go straight to experienced (manufacturable) formulation (and processing) space
- Does not rule out effective excipients based on rank-order or exaggerated binary results

